Polaryx Therapeutics, Inc.
PLYX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002075320
No open-market purchases or sales by Polaryx Therapeutics, Inc. insiders were filed in the last 90 days; 13 institutions reported holding it in 13F filings for Q2 2026, worth $5.83M in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding Polaryx Therapeutics, Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Q1 2026 | Change |
|---|---|---|---|
| Holders | 0 | 14 | +14 |
| Shares | 0 | 2.27M | +2.27M |
| Value | $0 | $17.1M | +$17.1M |
New holders (14)
Institutions that held Polaryx Therapeutics, Inc. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vanguard Capital Management LLC | 1,658,388 | $12.5M | 0.00% |
| Geode Capital Management, LLC | 170,673 | $1.29M | 0.00% |
| Millennium Management LLC | 127,525 | $964.1K | 0.00% |
| Vanguard Fiduciary Trust Co | 104,556 | $790.4K | 0.00% |
| State Street Corp | 58,104 | $439.3K | 0.00% |
| BlackRock, Inc. | 41,012 | $310.1K | 0.00% |
| Northern Trust Corp | 27,987 | $211.6K | 0.00% |
| Bank of America Corp | 25,881 | $195.7K | 0.00% |
| Goldman Sachs Group Inc | 13,483 | $101.9K | 0.00% |
| UBS Group AG | 13,479 | $101.9K | 0.00% |
| Squarepoint Ops LLC | 12,406 | $93.8K | 0.00% |
| Vanguard Global Advisers, LLC | 6,318 | $47.8K | 0.00% |
| Morgan Stanley | 5,543 | $41.9K | 0.00% |
| Tower Research Capital LLC (TRC) | 1,781 | $13.5K | 0.00% |
Sold out (0)
Institutions that held Polaryx Therapeutics, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
None.